Lucid Group fell in postmarket trading after posting a wider-than-anticipated loss for Q4, even as revenue more than doubled from a year ago. The EPS tally of -$3.62 was ...
Q4 2025 earnings call recap: production/delivery surge, Gravity ramp, Uber/Nuro robotaxi deal, 2026 guidance, margins and liquidity—read now.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results